Breast Cancer Coverage from Every Angle

Erika Hamilton, MD, on T-DXd for Metastatic Breast Cancer: Clinical Considerations

Posted: Friday, July 8, 2022

Erika Hamilton, MD, of Sarah Cannon Research Institute at Tennessee Oncology, discusses phase III data from the DESTINY-Breast03 study, which reinforced the consistent safety profile of fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive unresectable and/or metastatic breast cancer. Dr. Hamilton addresses nausea, alopecia, and pneumonitis, and offers clinical pearls on making treatment easier to tolerate.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.